The company held the 7th meeting of the 11th board of directors and the 7th meeting of the 10th board of supervisors to review and approve the annual work report and other related proposals
Release time:
2022-05-05
News from our newspaper # February 16 , Chairman Jiang Xiaomeng of the Group Company presided over the meeting of the 11th Board of Directors of the Company, it reviewed and approved 17 related reports and proposals such as 2021 annual board of directors report, 2021 annual general manager business report, 2021 annual report, 2021 annual financial final accounts report, 2021 annual profit distribution plan, etc.
General Manager's report pointed out that 2021 is the first year of the national "14th Five-Year Plan" , The management team, according to the company's five-year development plan and the annual management plan approved by the board of directors, focuses on the general working policy of "following the rules, keeping the right and bringing forth new ideas, reforming and innovating, and continuously improving, calmly deal with the new coronary pneumonia epidemic, raw material prices ups and downs, production restrictions and power restrictions and many other challenges, better to complete the work objectives set at the beginning of the year. As of the end of 2021 , the company's total assets were 70.24 .9 billion yuan, up 10.74% year-on-year, and the net assets attributable to shareholders of listed companies were 52.07 .3 billion yuan, up 17.39% year-on-year. For the whole year, operating income reached 38.05 .7 billion yuan, up 17.17% year-on-year, net profit attributable to shareholders reached 9.24 .1 billion yuan, up 58.12% year-on-year, and operating performance reached the best level in history.
2021, the company's cement plate industry chain extension war made new progress, holding the establishment of Hubei peak new building materials Co., Ltd., orderly promote the mechanism of sand project. Actively participated in the major asset restructuring of Tianshan shares and achieved good investment returns. All cement enterprises under the company continue to implement benchmarking management and fine management, carry out in-depth "three reductions and three improvements" activities, steadily implement various technological transformation work, strictly control production costs, and continuously improve the operation efficiency of enterprises. A total of cement clinker ,675 tons were sold throughout the year, up 28% year on year. Daye Peak manages the procurement of raw materials through multi-channel, open and transparent, and full supervision, and strictly controls the procurement cost while ensuring the quality. Continuously optimize the batching scheme, complete the technical transformation of the automatic batching system, increase the proportion of limestone in raw materials, and reduce the cost of raw materials; Continuously optimize the process parameters and use the MES system to trace the optimal parameters, combined with the implementation of more than ten technical transformations such as low-nitrogen combustion at the kiln end and dust collection system at the kiln end, the stability of the equipment has been improved, the overall production capacity of the kiln system has been improved, and the annual cement output has reached the best level in history. Yunnan Jianfeng strictly controls the procurement cost of raw materials by strengthening bidding management. Through the technical renovation of grate cooler, preheater and other equipment, the output of rotary kiln has been effectively increased. Affected by the completion of some key projects in the region and the commissioning of new cement production capacity, the competition in the cement market in this region has intensified and the price has dropped greatly. Therefore, the company further strengthened the regional market segmentation work according to market changes in time and formulated differentiated marketing strategies for different market segments, basically maintain the balance of production and sales. 2021 is the first complete year after Guizhou Jianfeng was put into production. Guizhou Jianfeng relies on the advanced second-generation new dry-process cement production line and adopts digital intelligent control technology to realize all-round intelligent management such as safe production, product quality, material consumption and energy consumption. Strengthen operator training, improve skill level, timely adjust and optimize process parameters, and ensure product quality stability; The whole line has reached the standard and reached the production capacity, coal consumption, electricity consumption, operation rate, kiln production, labor productivity and other indicators reached a good level.
2021, the company made progress in a number of technological innovations and engineering constructions in the pharmaceutical sector. The construction of the annual production of 20 .9 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical Co., Ltd. is progressing in an orderly manner. At present, the civil engineering and equipment installation and commissioning of the project have been basically completed, and the preliminary preparations for project acceptance and application for certification of cGMP are underway; new North Card and Peak North Card continue to implement comprehensive technological transformation, and intend to upgrade on the basis of existing pesticides and pharmaceutical intermediates, build a comprehensive research and development and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations in the pharmaceutical sector of the company. Jianfeng Pharmaceutical and its subsidiaries further increased their investment in research and development and completed the registration of moxifloxacin hydrochloride eye drops, lenvatinib mesylate capsules, valsartan amlodipine tablets and esomeprazole magnesium enteric-coated dry suspension 4 drugs. Peak pharmaceutical products won the bid for the first time in the national drug centralized procurement, olopatadine hydrochloride eye drops won the bid for the fourth batch of national drug centralized procurement, which is conducive to the market promotion of the product, sales have been greatly improved.
In addition, Jianfeng Health has completed the research and development of health food such as coenzyme Q10 soft capsule and broken ganoderma lucidum spore powder, and has obtained the record. Completed the development of many functional foods such as vitality V5 liquid drink and collagen liquid drink, and has now listed 6 ; "Development and Industrialization of Wall-broken Ganoderma lucidum Spore Powder for Enhancing Immunity" was approved by Jinhua Municipal Technology Innovation Project in 2021 . "Cranberry Extract" won the project of key high-tech products in Zhejiang Province in 2021 . Peak cable carried out the subway communication cable "Zhejiang manufacturing" standard construction work, high-speed data transmission with twisted pair communication cable through the "Zhejiang manufacturing" certification, won the representative of Zhejiang manufacturing benchmark "word mark". According to the development trend of regional trade and logistics, combined with the characteristics of the enterprise itself, Jianfeng International Trade has continuously improved its business development model and promoted the development of modern warehousing logistics, commodity supply chain and network freight platform business in an orderly manner. On the day of
, the company also held the st meeting of the 10th board of supervisors, deliberating and passing related reports and proposals such as the company's 2021 annual board of supervisors report. (remaining fruit)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page